TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00374660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 40 to 80 mg/m\^2 by dose escalations in 10 mg/m2 increments if no dose-limiting toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irofulven
Description: Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered as a 30-minute infusion on Days 1 and 15 of a 28-day cycle. The dose levels ranged from 0.30 to 0.40 mg/kg if no dose-limiting toxicity.
Study: NCT02040558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNK-010
Study: NCT00813137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox4 plus recombinant human endostatin (Endostar)
Description: Endostar 15mg iv drip D1\~7, D15\~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
Study: NCT03694314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: 200 ml drink. The drink contains 840 mg total of omega-3 (360 mg of DHA, 240 mg of EPA, 200 mg of alpha-linolenic acid, and 40 mg of DPA).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mL placebo fruit juice with no effect on the hypothesized outcome.
Study: NCT00415584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinacalcet HCl
Study: NCT03311230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive social incentive
Description: A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive social incentive
Description: Participants in this intervention will be competing against each other in the game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative social incentive
Description: Participants in this intervention will be working with each other in the game.
Study: NCT02500914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC-002
Description: SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
Study: NCT00077311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: 200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: 200 mcg sub Q on day 1 of each cycle if HgB \< or = 11 g/dL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg sub Q day 2 of each cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 mg sub Q day 2 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/sq m IV over 1 hr Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/sq m IV over 1 hr Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/sq m IV over 1 hr Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/sq m IV over 1 hr Day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNP7787
Description: 40 g IV over 30 min Day 1 of each cycle
Study: NCT04398615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable watch device
Description: Every study participant will be given a wearable watch device at the beginning of the study and will be instructed on how to use the device and to wear it continuously throughout the duration of the study (6 months total follow-up). The device will register biometric data and automatically archived. During the follow-up period both healthcare personnel and investigators will not be aware of data (including fall events) registered by the experimental device.
Study: NCT02961374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO
Study: NCT01871493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneous (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2605541
Description: Administered subcutaneous (SQ)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SQ
Study: NCT02961374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO
Study: NCT02291484

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac CT scan
Description: CT-guided management
Study: NCT03716674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metronome
Description: Patients completed 4 walking sessions of at least 10 minutes each. During each session, no auditory rhythm was given, or the rhythm of a Rhythmic Auditory Stimulation (RAS) adapted to the pace of comfort of each patient using a metronome was broadcasted via headphones. In all, 4 conditions were tested: walk with no RAS or an isochronous RAS or a random RAS or a RAS with an autocorrelated metronome rhythm.
Study: NCT01068301

Intervention type: DRUG
Group type: OTHER
Intervention: Plerixafor
Description: Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
Study: NCT00911313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole tablets (Femara; Novartis Pharma, Switzerland)
Description: 2.5 mg letrozole daily from day 3 of the menses for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin HCl (Cidophage®; CID,Cairo, Egypt)
Description: metformin HCl 1500 daily for 6-8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)
Description: 150 mg CC for 5 days starting from day 3 of menstruation
Study: NCT02529878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1/Paclitaxel chemotherapy plus Apatinib
Description: S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
Study: NCT02687490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: 125 mg/m2, D1, D8, D15
Study: NCT04275843

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Diet
Description: Consuming an traditional whole foods based diet for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modern Diet
Description: Consuming an processed formulation of the traditional diet for 4 weeks.
Study: NCT03975387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX295
Description: ASTX295 orally for 28-day cycle continuous or on an intermittent dosing schedule.
Study: NCT03277378

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lead placement followed by BurstDR stimulation
Description: lead placement followed by BurstDR stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lead placement followed by BurstDR stimulation
Description: lead placement followed by BurstDR stimulation
Study: NCT02810067

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunnel + AlloDerm
Description: A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel + Novomatrix
Description: A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (Novomatrix).
Study: NCT02409316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FES
Description: \[18F\]FES PET/CT scan
Study: NCT03230383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
Study: NCT01871493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SQ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered SQ
Study: NCT02957435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplerenone
Description: (Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
Study: NCT00474201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Gemfibrozil
Description: Control arm (no intervention used in this arm)
Study: NCT03207464

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]Methylreboxetine
Description: 8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [C-11]Methylreboxetine
Description: 8 individuals with Multiple Sclerosis and 4 healthy controls will undergo a \[C-11\]MRB PET scan and a MRI scan.
Study: NCT02069912

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative depression care management
Description: Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
Study: NCT03715972

Intervention type: DRUG
Intervention: Hydroxyurea
Description: info included in arm group

Intervention type: DRUG
Intervention: Acetazolamide
Description: Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.

Intervention type: DRUG
Intervention: Acetazolamide
Description: Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.

Intervention type: DRUG
Intervention: Acetazolamide
Description: Acetazolamide will not be considered a treatment; however, it will be used as a tool to help measure cerebralvascular reserve. A dose of 16 mg/kg ACZ will be administered with a maximum of 1400 mg.
Study: NCT02397954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
Study: NCT03928262

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Treatment 1: Benralizumab single dose, Treatment 2: Benralizumab single dose and Treatment 3: Benralizumab single dose subcutaneously administration on 36 healthy Chinese male and female subjects in 1:1:1 ratio.
Study: NCT02621489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: 2 mg Once Weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humulin kwickpen
Description: Humulin kwickpen 10U QD at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humulin kwickpen
Description: Humulin kwickpen 10U QD at bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 1g BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1g BID
Study: NCT03230383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06865571
Description: Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo for PF-06865571 for each cohort.
Study: NCT01007240

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyethylenimine (PEI) nanoparticles.
Study: NCT01033279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring and adjustment of oral anticoagulation
Description: Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
Study: NCT03853642

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling, Spirometry, Fraction exhaled Nitric Oxide
Study: NCT04875364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 2mg of Eszopiclone just before going to sleep.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eszopiclone
Description: 2mg of Eszopiclone just before going to sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: Constant oxygen flow at 4 Liters per minutes for the duration of time in bed via nasal cannula.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: A standard CPAP device will be provided using the settings as prescribed by the treating physician.
Study: NCT00790114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: Oral, day 1-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: single dose, twice during treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: single dose, twice during treatment
Study: NCT01583244

Intervention type: DRUG
Intervention: No Intervention (subjects were previously treated with Orencia®)
Description: No Intervention
Study: NCT00234156

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oral fructose and high fat diet
Description: High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: oral fructose and high fat diet
Description: High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (\~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.~Fructose in 360 ml water will be orally administered as 1.4 g/kg (\~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours.
Study: NCT01542021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix injection
Description: Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix injection
Description: Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: degarelix injection
Description: Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: androgen deprivation therapy
Study: NCT03776994

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinations on Day 0, Day 28, and Day 140
Description: The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinations on Day 0, Day 28, and Day 140
Description: The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinations on Day 0, Day 28, and Day 140
Description: The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinations on Day 0, Day 28, and Day 140
Description: The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinations on Day 0, Day 28, and Day 140
Description: The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccinations on Day 0, Day 28, and Day 140
Description: The monovalent VEE VLP vaccine (the same VEE VLP study agent which comprises the VEE portion of the NIAID trivalent alphaviral VLP vaccine) will use the same vaccination regimen (Day 0, Week 4 \[Day 28\], and Week 20 \[Day 140\]) and the vaccine dosages (2 μg, 10 μg, and 20 μg)
Study: NCT04676490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RECORD-ED Card
Description: Low-cost and low-tech recordable audio card containing language-concordant discharge instructions for families of children under age 10 presenting to the ED for asthma exacerbations with no or public insurance and a preference for English or Spanish. Recordable cards allow for multiple audio reviews of the instructions by multiple caregivers without dependence on access to the internet or smartphone technologies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RECORD-ED Patient Portal
Description: Audio recorded, language concordant discharge instructions via patient portal
Study: NCT01341340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus Eluting BVS
Description: Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)